Evidence map›Paper›PMID 28743272›Full record

ArticleMicrobial cell factories2017

Establishment of Neurospora crassa as a host for heterologous protein production using a human antibody fragment as a model product.

David Havlik, Ulrike Brandt, Kathrin Bohle, André Fleißner

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 43 citations in OpenAlex.

  1. Cell surface (Amsterdam, Netherlands) · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Heterologous protein production in filamentous fungi.Applied microbiology and biotechnology · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

David HavlikDivision of Pharmaceutical Biotechnology, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Inhoffenstr. 7, Braunschweig, 38124, Germany.
Ulrike BrandtInstitut für Genetik, Technische Universität Braunschweig, Spielmannstr. 7, 38106, Braunschweig, Germany.
Kathrin BohleDivision of Pharmaceutical Biotechnology, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Inhoffenstr. 7, Braunschweig, 38124, Germany.
André FleißnerInstitut für Genetik, Technische Universität Braunschweig, Spielmannstr. 7, 38106, Braunschweig, Germany. a.fleissner@tu-bs.de.ORCID http://orcid.org/0000-0001-5841-3199
Technische Universität Braunschweig · DEFraunhofer Institute for Toxicology and Experimental Medicine · DEProterixBio (United States) · US

Funding

Tools for Functional Analysis and Cell BiologyP01GM068087 · NIGMS · DARTMOUTH COLLEGE · PI DUNLAP, JAY C. · 2004 to 2013
$19.3M
NIGMS NIH HHS P01 GM068087
6 · The paper itself

Abstract

backgroundFilamentous fungi are commonly used as production hosts for bulk enzymes in biotechnological applications. Their robust and quick growth combined with their ability to secrete large amounts of protein directly into the culture medium makes fungi appealing organisms for the generation of novel production systems. The red bread mold Neurospora crassa has long been established as a model system in basic research. It can be very easily genetically manipulated and a wealth of molecular tools and mutants are available. In addition, N. crassa is very fast growing and non-toxic. All of these features point to a high but so far untapped potential of this fungus for biotechnological applications. In this study, we used genetic engineering and bioprocess development in a design-build-test-cycle process to establish N. crassa as a production host for heterologous proteins.

resultsThe human antibody fragment HT186-D11 was fused to a truncated version of the endogenous enzyme glucoamylase (GLA-1), which served as a carrier protein to achieve secretion into the culture medium. A modular expression cassette was constructed and tested under the control of different promoters. Protease activity was identified as a major limitation of the production strain, and the effects of different mutations causing protease deficiencies were compared. Furthermore, a parallel bioreactor system (1 L) was employed to develop and optimize a production process, including the comparison of different culture media and cultivation parameters. After successful optimization of the production strain and the cultivation conditions an exemplary scale up to a 10 L stirred tank reactor was performed.

conclusionsThe data of this study indicate that N. crassa is suited for the production and secretion of heterologous proteins. Controlling expression by the optimized promoter Pccg1nr in a fourfold protease deletion strain resulted in the successful secretion of the heterologous product with estimated yields of 3 mg/L of the fusion protein. The fungus could easily be cultivated in bioreactors and a first scale-up was successful. The system holds therefore much potential, warranting further efforts in optimization.

Indexed as

BioreactorsCulture MediaGlucan 1,4-alpha-GlucosidaseHumansHydrogen-Ion ConcentrationImmunoglobulin FragmentsNeurospora crassaPlasmidsPromoter Regions, GeneticRecombinant Fusion ProteinsCulture MediaGlucan 1,4-alpha-GlucosidaseImmunoglobulin FragmentsRecombinant Fusion ProteinsAntibody fragmentsBioreactorFusion proteinHeterologous proteinsNeurospora crassaProteases

Identifiers

PMID28743272
PMCPMC5526295
OpenAlexW2736550132

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.